NetTargets Inc.
11 Jan 2024
당사는 2024. 1. 11 이사회 결의에 따라 아래와 같이 주주배정방식의 신주발행을 공고합니다.
- 아 래 –
NetTargets will contribute its proprietary AI-based systems biology modeling technology to WOOJUNGBIO’s Open Innovation Project. By enabling quantitative simulation of biological responses and prediction of drug mechanisms, we are helping to shape a next-generation bioevaluation platform in the era of AI transformation.
NetTargets has been selected as one of the top 10 semifinalists among hundreds of drug discovery startups worldwide. The AI Discovery Award is an annual recognition by Nebius AI, a European AI-centric public cloud provider with global reach.